Biobeat Wearable Wrist and Chest Patient Monitoring Solutions Receives Class II Medical Device Approval from Health Canada

October 27, 2020

Biobeat provides wearable remote patient monitoring solutions for the healthcare continuum. Today they announced today that its wearable wrist and chest patient monitoring solutions have received Class II medical device approval (No. 320337) from Health Canada.

Biobeat reports their wireless wrist and chest monitoring solutions support health teams by transmitting real-time patient data from a distance, helping improve patient outcomes via accurate and reliable patient health updates and patient deterioration detection. These remote capabilities can be instrumental in helping monitor a variety of health conditions as well as mitigating the risk of infectious exposure, especially from COVID-19 patients.

“We are excited to receive the Health Canada Medical Device Class II approval, a significant milestone for our company, which will allow us to offer our innovative technologies to the Canadian healthcare market and help improve patient care,” said Arik Ben Ishay, CEO of Biobeat. “This registration underscores our mission to improve patient outcomes across the globe with our accurate wearable continuous patient monitoring solutions. We are eager to assist Canadian healthcare facilities and medical staff manage their patient workloads by using our advanced remote care abilities, especially during the current coronavirus pandemic.”

Maisha Labs, a Canadian digital health solution provider and integrator, assisted Biobeat throughout the licensing process and will continue to play a pivotal role in implementing the company’s solutions in healthcare facilities throughout the country. This includes an upcoming pilot project at The Jewish General Hospital and its Montreal-based Connected Health Futures Hub – OROT, orchestrated by a joint collaboration between Biobeat, Maisha Labs and the TransMedTech Institute, which will use Biobeat’s devices in a remote chronic care program.

Biobeat’s wearable wrist and chest-monitors utilize proprietary non-invasive reflective photoplethysmography monitoring technology to automatically and continuously track multiple vital signs and health parameters. The wireless solutions connect to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration. The management platform includes an integrated automated, customizable early warning score system that incorporates advanced health-AI-based algorithms that analyze aggregated patient data to identify deterioration more accurately.

SourceBiobeat
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version